Scott M. Dehm

The paper assesses CTC subset dynamics in mCRPC patients treated with 177Lu-PSMA-617 and finds that changes in PSMA and EpCAM-expressing CTCs correlate with survival outcomes.

This study uses proteomic profiling of extracellular vesicles to distinguish prostate cancer subtypes and identify subtype-specific biomarkers.

The paper identifies a subgroup of mCRPC characterized by LINE1 repeat DNA elements flanking the AR gene, which drive AR overexpression and confer resistance to androgen signaling inhibitors.

This paper identifies how PVT1 rearrangements in MYC+ cancers generate oncogenic peptides that synergistically activate MYC, AKT, and RAS-MAPK pathways, enhancing tumor aggressiveness.

The paper estimates the arrival time of clonal copy number gains in tumors and shows they promote mutational diversification and malignant growth.